Bajaj Healthcare Ltd

Bajaj Healthcare Limited has received a recommendation from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) for manufacturing and marketing of Cenobamate Tablets in various strengths (12.5mg to 200mg). This makes Bajaj Healthcare the first company in India to secure this recommendation for the next-generation antiseizure medication. Cenobamate is used for treating partial-onset seizures in adults. The company's Managing Director, Anil Jain, stated this is a significant regulatory milestone and reinforces their commitment to expanding their CNS therapies portfolio. Bajaj Healthcare plans to work with regulatory authorities for final approvals and commercialize the product, strengthening its position in specialty pharmaceuticals.

Bajaj Healthcare Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. This closure is in effect from June 23, 2026, until 48 hours after the definitive agreements for the sale of its operational business unit are signed, as disclosed on June 23, 2026. Additionally, the trading window will be closed from July 01, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct.

Bajaj Healthcare Ltd has approved the sale of its operational business unit located at Plot No. N-178, MIDC, Tarapur Industrial Area, Tarapur, Boisar, Palghar. The transaction, subject to definitive agreements, is expected to be completed by October 31, 2026, with a consideration of up to ₹4.05 Crores. The unit contributed 0.54% to revenue (₹3.31 Crores) and 0.74% to net worth (₹3.97 Crores) in the last financial year. The buyer, M/s Orchem Products, is not a promoter/group company, and the transaction is confirmed as not a related party transaction. The trading window for company securities will remain closed until 48 hours after the formal execution of agreements.

Anil Champalal Jain, Managing Director and member of the Promoter Group of Bajaj Healthcare Limited, has acquired 1,00,000 equity shares of the company through open market transactions on June 12, 2026. This acquisition represents 0.297% of the total share capital. Following this transaction, his total holding in the company, along with PACs, has increased to 20,36,544 equity shares, constituting 6.050% of the total share capital. The disclosure was made in compliance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Bajaj Healthcare Ltd announced its FY26 results, reporting a 12.6% increase in revenue and a 27.1% rise in Profit After Tax (PAT) from continuing operations. API exports grew by 51.6%, and the formulations business also saw a 12.6% increase. The company filed 41 DMFs in Q4, bringing the total to 110. Cenobamate is progressing through Phase III clinical trials, slated for launch in Q2 FY27. The company completed the conversion of warrants into equity shares, bringing in ₹527 million.

Bajaj Healthcare Ltd. has released the Monitoring Agency Report for the quarter ended March 31, 2026, as per SEBI regulations. The report, issued by CARE Ratings Limited, pertains to the utilization of ₹204.97 crore raised through a preferential issue of equity shares and conversion of warrants. The report indicates no deviation from the stated objectives of the issue proceeds. The monitoring agency declares an objective view based on provided information, without performing an audit or independent verification.

Bajaj Healthcare Ltd's board has recommended a final dividend of ₹1.5 per equity share (30% of face value of ₹5 each) for the financial year 2025-26, subject to shareholder approval. The decision was made during the board meeting held on May 08, 2026, where the audited standalone financial results for the quarter and year ended March 31, 2026, were also approved. The company reported a profit of ₹2,131.04 Lakhs after tax from continuing operations for the year ended March 31, 2026.

Bajaj Healthcare Ltd announced its audited standalone financial results for the year ended March 31, 2026. Key highlights include a final dividend recommendation of 30% (₹1.50 per share), the appointment of M/s. JCR & Co. LLP as Internal Auditors for FY27, and the re-appointment of M/s. V.J. Talati & Co. as Cost Auditors for FY27. The company's revenue from operations for FY26 stood at ₹61,103.14 lakhs.

Bajaj Healthcare Ltd's board approved the audited standalone financial results for the quarter and financial year ended March 31, 2026. The company reported revenue from operations of ₹61,103.14 lakhs for FY26. A final dividend of 30% (₹1.50 per share) was recommended, subject to shareholder approval. M/s. JCR & Co. LLP appointed as Internal Auditors for FY27, and M/s. V.J. Talati & Co. re-appointed as Cost Auditors for FY27.

Bajaj Healthcare Ltd's board approved the audited standalone financial results for the quarter and year ended March 31, 2026. The company reported revenue from operations of ₹61,103.14 lakhs for FY26. A final dividend of 30% (₹1.50 per share) was recommended, subject to shareholder approval. M/s. JCR & Co. LLP were appointed as Internal Auditors for FY27, and M/s. V.J. Talati & Co. re-appointed as Cost Auditors for FY27.